Compare GDHG & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDHG | CVM |
|---|---|---|
| Founded | 2008 | 1983 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1M | 32.4M |
| IPO Year | 2022 | 1996 |
| Metric | GDHG | CVM |
|---|---|---|
| Price | $1.83 | $3.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.0K | ★ 42.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.16 | $0.18 |
| 52 Week High | $8.69 | $13.48 |
| Indicator | GDHG | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 36.56 |
| Support Level | $1.56 | $2.02 |
| Resistance Level | $2.30 | $6.71 |
| Average True Range (ATR) | 0.21 | 0.38 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 32.22 | 22.10 |
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, it manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants. it opearts in the Cayman Islands, PRC, BVI, and HK.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.